MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyae328

Медицинская библиотека · The oncologist · 2025

Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational study.

Narita Yukiya, Mizuno Taro, Ishizuka Yasunobu, Sakakida Tomoki, Masuishi Toshiki, Taniguchi Hiroya, Kadowaki Shigenori, Honda Kazunori, Ando Masashi, Tajika Masahiro, Takahari Daisuke, Muro Kei

СтатьяНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

PURPOSE: Human epidermal growth factor receptor 2 (HER2) status is a critical biomarker in advanced gastric cancer (AGC). While the role of HER2-positive tumors in guiding targeted therapies is well-established, the clinical implications of HER2-low expression, defined as immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative (ISH-negative), remain undetermined. The aim of this study was to investigate the prognostic significance and clinicopathological features of HER2-low AGC.

PATIENTS AND

METHODS

This retrospective analysis involved patients with AGC treated with first-line fluoropyrimidine and platinum-based chemotherapy from 2011 to 2020. Patients were categorized into HER2-zero (HER2 IHC 0), HER2-low (IHC 1+ or 2+/ISH-negative), and HER2-positive (IHC 2+/ISH-positive or 3+) groups.

RESULTS

Among 548 patients analyzed, 33.0%, 45.1%, and 21.8% were classified as HER2-zero, HER2-low, and HER2-positive, respectively. The proportions of male patients, intestinal-type histology, esophagogastric junction/cardia involvement, metastatic disease status, ≥2 metastatic sites, liver metastasis, lymph node metastasis, and high serum carcinoembryonic antigen levels were gradually elevated in the HER2-zero, HER2-low, and HER2-positive groups. Overall survival (median) was 13.8, 13.6, and 23.0 months, respectively, with a non-significant trend favoring HER2-positive over HER2-low (adjusted hazard ratio: 0.80; P = .0672). A delayed separation of Kaplan-Meier curves for overall survival between the HER2-zero and HER2-low groups was observed, without reaching statistical significance (adjusted hazard ratio: 1.12; P = .2568).

CONCLUSION

Patients with HER2-low status exhibited intermediate and specific clinicopathological features within the HER2-negative category. In terms of prognosis, HER2-low patients showed a worsening trend compared with HER2-positive patients. This evidence implies that HER2-low status represents a distinct clinical subset, bridging the gap between the HER2-zero and HER2-positive profiles.

Для цитирования: Narita Yukiya, Mizuno Taro, Ishizuka Yasunobu, Sakakida Tomoki, Masuishi Toshiki, Taniguchi Hiroya, Kadowaki Shigenori, Honda Kazunori, Ando Masashi, Tajika Masahiro, Takahari Daisuke, Muro Kei. Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational study.. The oncologist. 2025. DOI: 10.1093/oncolo/oyae328.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.